Endo International

Endo International Plc operates as a pharmaceutical company, which engages in the development, manufacture, and distribution of branded and generic pharmaceutical products. It operates through the following segments: Branded Pharmaceuticals, Sterile Injectables, Generic Pharmaceuticals and International Pharmaceuticals. The Branded Pharmaceuticals segment conducts certain operations in the U.S. through leased and owned manufacturing properties in Pennsylvania, New York and New Jersey, as well as certain administrative and R&D functions through leased properties in Pennsylvania. The Sterile Injectables segment includes manufacturing, quality assurance, research and development, and administration functions. The Generic Pharmaceuticals segment is composed of manufacturing, distribution, quality assurance and administration functions, as well as certain research and development functions. The International Pharmaceuticals segment’s operations are currently conducted through Paladin’s leased headquarters in Montreal, Canada. The company was founded in 1997 and is headquartered Dublin, Ireland.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Endo Health Solutions Inc. provides specialty healthcare solutions in the United States and internationally. The company’s Endo Pharmaceuticals segment offers branded prescription products,.

AmerisourceBergen

Amneal Pharmaceuticals

Johnson & Johnson

McKesson

Mallinckrodt PLC

Teva Pharmaceutical

Shares of some manufacturers and distributors of opioid drugs decline on Tuesday following reports that a criminal probe has been initiated by federal prosecutors.

Fed Reportedly Opens Criminal Investigation on Opioid Makers

Cardinal Health

Shares of the companies embroiled in opioid litigation fell in afternoon trading afterThe Wall Street Journal reported the federal government had opened a criminal investigation into some opioid makers and distributors, citing sources.

Shares of opioid makers and distributors drop on criminal probe

Mylan

Shares of generic drugmakers are up in morning trading, with Mallinckrodt  leading the pack as its stock rallied 15%. Teva Pharmaceutical Industries Ltd.

Shares of generic drugmakers jump in morning trading

The FDA accepts Endo's (ENDP) BLA for CCH for the treatment of cellulite in the buttocks.

Endo's (ENDP) BLA for Cellulite Treatment Accepted by FDA

Endo International  said this week that Paul Campanelli, president and CEO, will step down when a successor is named. A successor has not yet been appointed.

Endo CEO to step down when successor is named

Endo International plc (ENDP) CEO Paul Campanelli on Q3 2019 Results - Earnings Call Transcript

Endo (ENDP) reports better-than-expected results for the third quarter as Xiaflex delivers a strong performance.

Endo (ENDP) Q3 Earnings & Revenues Beat Estimates, Down Y/Y

Endo (ENDP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Earnings Preview: Endo International (ENDP) Q3 Earnings Expected to Decline

Endo International plc (NASDAQ: ENDP) shares were trading lower Thursday after the company announced it will present data on the use of a standing MRI versus a prone MRI for the evaluation of cellulite at the Annual Meeting of the American Society for Dermatologic Surgery in Chicago.

Why Are Endo Shares Trading Lower?

Investors are excited about the potential for a settlement in opioid litigation.

Why Endo International Stock Is Skyrocketing Today

Endo Still Not Worth It

It looks like a short-squeeze scenario is unfolding.

The Most Likely Reason Endo International Shares Are Soaring Today

BioSpecifics Technologies

FibroGen

Vaxart

Endo International (ENDP) files BLA for collagenase clostridium histolyticum (CCH) for the treatment of cellulite in the buttocks.

Endo Files BLA for CCH With the FDA for Cellulite Candidate (Revised)

Endo International (ENDP) files BLA for the additional indication of Xiaflex [collagenase clostridium histolyticum (CCH)] for the treatment of cellulite in the buttocks.

Endo International Files BLA for Label Expansion of Xiaflex

In an era where health-consciousness and looking svelte is more important than ever, cosmetic surgery and cosmetic products have yet to lose favor with consumers and investors.

Endo Shares Climb On Potential Treatment for Cellulite

DocuSign

Guidewire Software

Earnings and other factors continued to provide a lift to some stocks.

Why DocuSign, Endo International, and Guidewire Software Jumped Today

The pharma company's legal settlement with two Ohio counties and its regulatory filing for a new drug pleased investors.

Why Endo International Stock Is Soaring Today

Endo International PLC (NASDAQ: ENDP) shares jumped on Friday after the company announced that it has submitted a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for collagenase clostridium histolyticum (CCH) for the treatment of cellulite in the buttocks.

New Cellulite Study Submission Could Be a Big Hit

Concerns about a possible bankruptcy filing by another opioid maker are taking a big toll on Endo.

Why Endo International Shares Are Tanking Today

Endo (ENDP) receives an FDA approval for the generic equivalent of Swedish Orphan Biovitrum's Orfadin.

Endo Gains FDA Nod for Orfadin Generic to Treat Rare Disease

Endo (ENDP) reported earnings 30 days ago. What's next for the stock?

Endo (ENDP) Up 5.8% Since Last Earnings Report: Can It Continue?

Allergan

Thousands of pending opioid-abuse lawsuits against several pharma companies come into limelight after the Oklahoma ruling against J&J. Let's see what's in store for these companies.

Will Opioid Litigation Take its Toll on Pharma Companies?

Endo (ENDP) finally has some good news for investors with the settlement of a few cases in Ohio related to opioid medications.

Endo Up on Settlement of a Few Cases Related to Opioid Drugs

Investors need to pay close attention to Endo (ENDP) stock based on the movements in the options market lately.

Are Options Traders Betting on a Big Move in Endo (ENDP) Stock?

Baidu

Hilton Worldwide Holdings

Despite some nervousness in the broader market, earnings and other good news helped boost these stocks.

News for Endo International Stock (ENDP)